Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.53 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | VDR | P11473 | 1/20 | 0.51 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | CDC25A | P30304 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6387174 | 1.00 | NPC1L1 (0.73) | NPC1L1MEN1USP2LMNATP53 | |
| SCHEMBL29354605 | 0.92 | NPC1L1 (0.72) | NPC1L1MEN1USP2LMNATP53 | |
| SCHEMBL6391409 | 0.86 | NPC1L1 (0.73) | NPC1L1MEN1USP2LMNATP53 | |
| SCHEMBL7124642 | 0.86 | NPC1L1 (0.73) | NPC1L1MEN1USP2LMNATP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL23647982 | 0.84 | NPC1L1 (1.00) | NPC1L1MEN1USP2LMNATP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL3421500 | 0.84 | NPC1L1 (1.00) | NPC1L1MEN1USP2LMNATP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL14490136 | 0.84 | NPC1L1 (1.00) | NPC1L1MEN1USP2LMNATP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL21000300 | 0.84 | NPC1L1 (1.00) | NPC1L1MEN1USP2LMNATP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL14360501 | 0.84 | NPC1L1 (1.00) | NPC1L1MEN1USP2LMNATP53 | |
| Cholestan-3Beta,5Alpha,6Beta-Triol SCHEMBL15935528 | 0.84 | NPC1L1 (1.00) | NPC1L1MEN1USP2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004382-A1 | Meiosis regulating compounds | GRONDAHL CHRISTIAN (DK) | 2005-01-06 | — | — | US | claimed |
| EP-0946584-B1 | Meiosis regulating compounds | NOVO NORDISK AS (DK) | 2003-04-23 | — | — | EP | claimed |
| US-20030032824-A1 | Meiosis regulating compounds | GRONDAHL CHRISTIAN (DK) | 2003-02-13 | — | — | US | claimed |
| US-20010005757-A1 | Meiosis regulating compounds | GRONDAHL CHRISTIAN (DK) | 2001-06-28 | — | — | US | claimed |
| EP-0946584-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-10-06 | — | — | EP | claimed |
| WO-1998028323-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-07-02 | — | — | WO | claimed |
| US-20050004382-A1 | Meiosis regulating compounds | GRONDAHL CHRISTIAN (DK) | 2005-01-06 | — | — | US | disclosed |
| US-6759400-B2 | Meiosis regulating compounds | NOVO NORDISK A/S (DK) | 2004-07-06 | — | — | US | disclosed |
| EP-0946584-B1 | Meiosis regulating compounds | NOVO NORDISK AS (DK) | 2003-04-23 | — | — | EP | disclosed |
| US-20030032824-A1 | Meiosis regulating compounds | GRONDAHL CHRISTIAN (DK) | 2003-02-13 | — | — | US | disclosed |
| US-6486145-B2 | STEROL DERIVATIVE USEFUL IN TREATMENT OF FERTILITY | NOVO NORDISK A/S (DK) | 2002-11-26 | — | — | US | disclosed |
| US-20010005757-A1 | Meiosis regulating compounds | GRONDAHL CHRISTIAN (DK) | 2001-06-28 | — | — | US | disclosed |
| EP-0946584-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028323-A1 | MEIOSIS REGULATING COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032824-A1 | Meiosis regulating compounds | MNS1, NR5A1, NASP | NPC1L1 2280/4885MEN1 231/4885USP2 4505/4885 |
| US-20010005757-A1 | Meiosis regulating compounds | MNS1, NR5A1, NASP | NPC1L1 2280/4885MEN1 231/4885USP2 4505/4885 |
| US-20050004382-A1 | Meiosis regulating compounds | NASP, MNS1, NR5A1 | NPC1L1 2324/4885MEN1 336/4885USP2 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.